The National Institute for Health and Care Excellence (NICE) has made a significant stride in the management of advanced melanoma by approving the drug combination of nivolumab and relatlimab as a first-line treatment.
Regulatory
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
FDA Fast Tracks Naporafenib for Unresectable, Metastatic Melanoma
The Phase III SEACRAFT-2 trial will analyze the clinical efficacy of naporafenib compared with physician’s choice of single-agent dacarbazine, temozolomide, or trametinib among patients with NRAS-mutated metastatic melanoma who received prior treatment with an immunotherapy.
FDA Approves 3 Treatments, Cancer Vaccine Shows Promise
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.